NOXCOVID has been cleared to recruit patients for the 800 mg and 1200 mg cohorts, which means that there were no safety concerns with the 400 mg and 600 mg groups. The announcement did not comment on efficacy.
On the same day, Noxopharm announced the formation of a dedicated subsidiary to exploit its STING-inhibition technology.
Coincidence?
NOXCOVID has been cleared to recruit patients for the 800 mg and...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
